Publications

by | September 25, 2012 | Uncategorized

European Voice Event – “Righting Wrongs: will clinical trials get a new deal in Europe?”

On 24 September EPHA attended an event on the European Commission proposal for a regulation repealing and replacing the existing clinical trials framework. The workshop, hosted by the pan-European newspaper, European Voice, as a part of its ‘Health Check Debates’ series, featured representatives from DG Health and Consumer Policy (SANCO), the European Federation of Pharmaceutical Industries and Associations (EFPIA), the European Organisation for Research and Treatment of Cancer (EORTC) and the European Patients’ Forum (EPF).

The event sought to establish how far the Commission’s new proposal on clinical trials on medicinal products for human use will go in addressing the criticisms made against the existing legal framework. As outlined in the EPHA assessment of the revised rules, the new regulation attempts to reduce costly and time-consuming administrative barriers, encourage greater investment in clinical trials in Europe and ensure the safety of patients.

The event was opened with a brief statement from each panelist, outlining their concerns with regards to the revision of clinical trials. Anastassia Negrouk of EORTC highlighted the initial burden upon member states when changing to the new system, and questioned the potential implementation of the proposals, particularly where states are heavily invested in their current systems. Kaisa Immonen-Charalambous from EPF noted three concerns from the patients’ perspective – access to clinical trial results, information and informed consent, and patient involvement in the clinical trial process.

Since patients ultimately bear the risk, she said, they have a moral right to be involved in the clinical trial process. Richard Bergstrom, director-general of EFPIA, voiced his concerns about the loss of competitiveness and compromised nature of the Commission’s proposal. He emphasised that the industry welcomes the reform but noted that, since it already seeks to balance a number of diverse interests, following a long process of consultation, it is a compromised proposal from the outset and must be protected from too much amendment and ‘watering down’. Finally, Stefano Soro, head of unit for quality, safety and efficacy of medicinal products, listed three considerations that were high on the Commission’s agenda when drafting the new proposal. These were: the need to make Europe attractive for the conduct of clinical trials, the need to highlight the importance of academic research in this area, and the danger of harming smaller (and primarily academic) trial centres if a heavily-centralised system is put in place.

How then might all these national and EU elements be brought together into one, coherent, clear process? What is the significance of the separation between the ethical and the regulatory parts of this process? Should and will the publication of all clinical trials results and data be made mandatory? Does the political will exist to push this dossier forward? What hurdles are envisaged in this process?

The moderator moved first to address the issue of splits between ethical and regulatory aspects and coordination between national and EU level parts of the process. The Commission asserted that ethical and regulatory aspects are not categorised so clearly, but that elements of the process are divided according to the level at which they are most appropriately conducted. EFPIA refuted this claim, stating that the split is a reality – regulation is fairly standard amongst member states but the requirements and operating procedures of the ethics committees varies dramatically between states. This is most problematic for the small academic researchers, who have less freedom to chose those committees with the least burdensome practices. An audience member representing the ethics committee of a medical school in Vienna made a short presentation opposing the characterisations made by both the Commission and the industry – ethics committees, he said, are able to perform within the given time constraints when operated efficiently, but the shorter the timeline, the lower the quality of assessment.

Addressing the political will required to bring about a set of regulations which will put considerable burden upon Member States, the Commission reaffirmed its assertion that the proposal is sound, but acknowledged that some negotiating with Member States may be necessary. The industry representative warned of the danger in provoking resistance from larger pharmaceutical companies if the regulation gets too complex, since they are not losing out under the current system. EPF stated that patient concerns regarding this issue are fairly uniform across Europe and indicated that they would have favoured a more harmonised, EU-level approach in this case.

The discussion briefly turned to the provisions regarding insurance – these are welcomed as they provide for the creation of national indemnity schemes, instead of each trial requiring its own insurance. The Commission highlighted a statistic which says that in 2010, 75 million euros was spent on insurance whilst only 200,000 euros was paid out in claims against these policies. This is particularly damaging to small academic centres, where public money is taken to conduct the trial, but is used to fund the insurance rather than to further research.

Finally, the provisions regarding the publishing of clinical trials results and data was discussed. Both the Commission and industry representatives reiterated that most data is already available and that some remains unsuitable for publication as a result of its commercial sensitivity. Richard Bergstrom highlighted the recent agreement on transparency by the European Medicines Agency (EMA) and their upcoming workshop (22 November 2012) on transparency issues. Stefano Soro reported on the continued work to create a single portal for all data relating to clinical trials and emphasised that the Commission’s approach is that all information be open unless otherwise stated. Finally, EPF noted the importance of open information for researchers, in particular that information from trials which have failed or not been continued, and the need for patients to be given access to data without the need for expensive subscriptions to scientific journals.

The clinical trials file is currently under discussion in the European Parliament and the Council.

—-

EPHA related articles

Get the EPHA Newsletter

The best of our activities, right in your inbox!